Clinical utility of digital technologies in Parkinson’s disease

Publikation: Beitrag in FachzeitschriftÜbersichtsartikel (Review)BeigetragenBegutachtung

Beitragende

  • Björn Falkenburger - , Klinik und Poliklinik für Neurologie (Autor:in)
  • Alessandra Fanciulli - , Medizinische Universität Innsbruck (Autor:in)
  • Monika Pötter-Nerger - , Universität Hamburg (Autor:in)
  • Thilo van Eimeren - , Universität zu Köln (Autor:in)
  • Joseph Classen - , Universität Leipzig (Autor:in)
  • Günter Höglinger - , Ludwig-Maximilians-Universität München (LMU), Munich Cluster for Systems Neurology (SyNergy) (Autor:in)
  • Christoph Redecker - , Universität Bielefeld (Autor:in)
  • Jürgen Winkler - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Jochen Klucken - , University of Luxembourg (Autor:in)

Abstract

Digital health technologies (DHTs) are on the verge of changing treatment of Parkinson’s disease (PD). This narrative overview article describes DHTs that are already used or in development, focusing on technologies available in Germany and on their clinical utility. Examples include applications that are primarily used by patients, i.e., tools for patient education and empowerment, but also stand-alone interventions improving clinical outcomes including motor and non-motor symptoms. In Germany, these patient-centered DHTs fall under the HTA framework of digital health applications (DIGA). DHT for telemonitoring, in contrast, are designed to support physicians and other healthcare providers and therefore medical devices. DHT are also used increasingly as exploratory endpoints in trials testing neuroprotective treatments.

Details

OriginalspracheEnglisch
FachzeitschriftJournal of Neural Transmission
PublikationsstatusElektronische Veröffentlichung vor Drucklegung - 12 Nov. 2025
Peer-Review-StatusJa

Externe IDs

PubMed 41222710